Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Buserelin→

Buserelin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57982-77-1
Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Drug class
Gonadotropin-releasing hormone (GnRH/LHRH) agonist analogue
Mechanism of action
Initially stimulates pituitary gonadotropin release; sustained exposure down-regulates the hypothalamic-pituitary-gonadal axis and suppresses gonadotropin and gonadal-steroid secretion.
Indications / reported uses
  • Pituitary desensitisation before gonadotrophin-based ovulation induction in assisted reproduction (injection product information; other formulations may have different indications)

Sources: UK SmPC (eMC)

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Buserelin Environmental Risk Assessment (ERA) (the Buserelin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.